Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Sulindac. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 known ✓ | P35354 | 2/20 | 0.68 |
| ▸ | PTGS1 known ✓ | P23219 | 1/20 | 0.68 |
| ▸ | PPARG | P37231 | 14/20 | 0.77 |
| ▸ | RXRA | P19793 | 6/20 | 0.71 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.70 |
| ▸ | MAPT | P10636 | 3/20 | 0.70 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.70 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.70 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.70 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.70 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.70 |
| ▸ | GLA | P06280 | 1/20 | 0.70 |
| ▸ | TSHR | P16473 | 1/20 | 0.70 |
| ▸ | EDNRA | P25101 | 1/20 | 0.70 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.70 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.70 |
| ▸ | EGFR | P00533 | 1/20 | 0.68 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.68 |
| ▸ | DRD1 | P21728 | 1/20 | 0.68 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sulindac SCHEMBL4203 | 0.99 | PPARG (0.78) | PPARGRXRACYP1A2MAPTMAPK1 | |
| Sulindac SCHEMBL29360981 | 0.99 | PPARG (0.78) | PPARGRXRACYP1A2MAPTMAPK1 | |
| Sulindac SCHEMBL30901384 | 0.99 | PPARG (0.78) | PPARGRXRACYP1A2MAPTMAPK1 | |
| Sulindac SCHEMBL2029754 | 0.99 | PPARG (0.78) | PPARGRXRACYP1A2MAPTMAPK1 | |
| Sulindac SCHEMBL4202 | 0.99 | PPARG (0.78) | PPARGRXRACYP1A2MAPTMAPK1 | |
| Sulindac SCHEMBL31324645 | 0.99 | PPARG (0.78) | PPARGRXRACYP1A2MAPTMAPK1 | |
| Sulindac SCHEMBL6903607 | 0.99 | PPARG (0.78) | PPARGRXRACYP1A2MAPTMAPK1 | |
| Sulindac SCHEMBL30989491 | 0.99 | PPARG (0.78) | PPARGRXRACYP1A2MAPTMAPK1 | |
| Sulindac Sulfoxide SCHEMBL11255653 | 0.99 | PPARG (0.78) | PPARGRXRACYP1A2MAPTMAPK1 | |
| Sulindac Sulfoxide SCHEMBL755984 | 0.99 | PPARG (0.78) | PPARGRXRACYP1A2MAPTMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1830 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3841097-B1 | 2,6-BIS(((1H-BENZO[D]IMIDAZOL-2-YL)THIO)METHYL)PYRIDINE AND N2,N6-DIBENZYLPYRIDINE-2,6-DICARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS PHOSPHOINOSITIDE 3-KINASE (PI3K) INHIBITORS FOR TREATING CANCER | BIOMEDICAL RES FOUNDATION OF THE ACADEMY OF ATHENS BRFAA (GR) | 2026-05-20 | — | — | EP | claimed |
| US-20250213585-A1 | COMPOSITIONS AND METHODS OF A CONCOMITANT THERAPY OF ALTERNATING ELECTRIC FIELDS AND NOTCH-1 INHIBITOR | SHANGHAI INSTITUTE OF BIOCHEMISTRY AND CELL BIOLOGY (CN) | 2025-07-03 | — | — | US | claimed |
| US-20250032503-A1 | USE OF APREPITANT FOR TREATING ALZHEIMER'S DISEASE | HOTH THERAPEUTICS, INC. | 2025-01-30 | — | — | US | claimed |
| CN-112770764-B | Methods of treating infections using bacteria | 因达普特斯治疗有限公司 | 2024-12-03 | — | — | CN | claimed |
| CN-118853779-A | Preparation method and application of sulindac and intermediate thereof | 江苏暨明医药科技有限公司 | 2024-10-29 | — | — | CN | claimed |
| WO-2024218483-A1 | SULINDAC AND/OR SULINDAC SULFIDE FOR THE TREATMENT OF ANGELMAN SYNDROME | HEALX LTD (GB) | 2024-10-24 | — | — | WO | claimed |
| CN-118207152-A | Culture solution capable of promoting growth and improving functions of vascular endothelial stem cells | 张易 | 2024-06-18 | — | — | CN | claimed |
| CN-118079006-A | Skin composition | 国立大学法人东京医科齿科大学 | 2024-05-28 | — | — | CN | claimed |
| EP-3856213-B1 | METHODS OF TREATMENT OF INFECTIONS USING BACTERIA | INDAPTUS THERAPEUTICS INC (US) | 2024-03-06 | — | — | EP | claimed |
| EP-4297868-A1 | USE OF APREPITANT FOR TREATING ALZHEIMER'S DISEASE | Hoth Therapeutics, Inc. (US) | 2024-01-03 | — | — | EP | claimed |
| US-6231888-B1 | DRUG DELIVERY FOR DRUGS WITH CORES AND COATINGS | PERIO PRODUCTS LTD. (IL) | 2001-05-15 | — | — | US | claimed |
| EP-1078043-A1 | NEW APOPTOTIC BODIES, MONOCYTE DERIVED CELLS CONTAINING THE SAME, A PROCESS FOR THEIR PREPARATION AND THEIR USES AS VACCINES | I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale (FR) | 2001-02-28 | — | — | EP | claimed |
| WO-2000033790-A2 | METHODS AND COMPOSITIONS FOR PREVENTION AND TREATMENT OF ARTERIAL LESIONS WITH NON-STEROIDAL ANTI-INFLAMMATORY DRUGS | THE ROCKEFELLER UNIVERSITY (US) | 2000-06-15 | — | — | WO | claimed |
| WO-2000033848-A1 | METHODS AND COMPOSITIONS FOR PREVENTION AND TREATMENT OF RESTENOSIS WITH NON-STEROIDAL ANTI-INFLAMMATORY DRUGS | THE ROCKEFELLER UNIVERSITY (US) | 2000-06-15 | — | — | WO | claimed |
| WO-2000028974-A1 | LOCAL DELIVERY OF DRUGS TO THE COLON FOR LOCAL TREATMENT OF COLONIC DISEASES | DEXXON LTD. (IL) | 2000-05-25 | — | — | WO | claimed |
| EP-0963200-A2 | METHODS AND COMPOSITIONS FOR INHIBITION OF ANGIOGENESIS | The Children's Medical Center Corporation (US) | 1999-12-15 | — | — | EP | claimed |
| WO-1999058645-A1 | NEW APOPTOTIC BODIES, MONOCYTE DERIVED CELLS CONTAINING THE SAME, A PROCESS FOR THEIR PREPARATION AND THEIR USES AS VACCINES | I.N.S.E.R.M. (Institut National de la Santé et de la Recherche Médicale) (FR) | 1999-11-18 | — | — | WO | claimed |
| EP-0942753-A1 | COMBINATIONS FOR USE IN INCREASING THE POTENCY OF A SUBSTRATE FOR MULTIDRUG RESISTANCE RELATED PROTEIN | Dublin City University (IE) | 1999-09-22 | — | — | EP | claimed |
| WO-1998019649-A2 | METHODS AND COMPOSITIONS FOR INHIBITION OF ANGIOGENESIS | THE CHILDREN'S MEDICAL CENTER CORPORATION (US) | 1998-05-14 | — | — | WO | claimed |
| WO-1998018490-A1 | COMBINATIONS FOR USE IN INCREASING THE POTENCY OF A SUBSTRATE FOR MULTIDRUG RESISTANCE RELATED PROTEIN | DUBLIN CITY UNIVERSITY (IE) | 1998-05-07 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250032503-A1 | USE OF APREPITANT FOR TREATING ALZHEIMER'S DISEASE | TACR1, ACHE, TACR2 | PTGS2 689/4885PTGS1 437/4885PPARG 1791/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.